Alnylam Pharmaceuticals said this week that it has formed a collaboration with Medtronic and the CHDI Foundation to advance an siRNA-based treatment for Huntington's disease.
The drug, ALN-HTT, comprises an siRNA against huntingtin, the gene responsible for the disease, and a Medtronic-developed implantable infusion system designed to deliver the agent to the central nervous system.
CDHI, a non-profit firm focused on advancing Huntington's disease treatments, has agreed to initially fund up to 50 percent of the activities required to advance ALN-HTT up to an investigational new drug application filing.
Alnylam and Medtronic will maintain their existing 50/50 partnership on the drug, originally established in 2005 (GSN 2/11/2005).